Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study

Nanas, John N.; Alexopoulos, George P.; Anastasiou-Nana, Maria; Karidis, K.; Tirologos, Argiris; Zobolos, Spyridon; Pirgakis, Vlasios; Anthopoulos, L.; Sideris, Dimitrios; Stamatelopoulos, S.; Moulopoulos, Spyridon D.

doi:10.1016/s0735-1097(00)01025-1

Cited by 71 publications

(40 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies have compared low-and high-dose ACE-inhibitors but are substantially limited compared to ATLAS and NETWORK in terms of statistical power to assess mortality and outcome. [30][31][32] Overall, these trials demonstrate a potential advantage of higher doses in terms of improved symptoms and reduced frequency of hospitalizations, but do not provide conclusive proof that higher doses improve survival. These results may have led to less aggressive recommendations and guidelines regarding titration of ACE-inhibitors and ARBs in HF patients as compared to b-blockers.…”

Section: Target Doses Of Ace-inhibitors and Angiotensin Receptor Blocmentioning

confidence: 90%

What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients?

Waqar

Dunlap

Gerson

2012

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

Section: Target Doses Of Ace-inhibitors and Angiotensin Receptor Blocmentioning

confidence: 90%

What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients?

Waqar

Dunlap

Gerson

2012

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

“…The main clinical studies are summarized in Table II. Absence of dose-dependency was noted by Nanas et al, 32 where standard and high doses of enalapril were compared. This trial addressed whether doses above those studied in the landmark trials were superior.…”

Section: Clinical Outcomesmentioning

confidence: 90%

“…The two exceptions include Nanas et al, 32 which concluded that doses higher than recommended did not have any added benefit, and the NETWORK trial, 35 which might not have been powered to detect a difference in dosing outcomes, as it had fewer patients and shorter duration of follow-up compared with the ATLAS study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

What is the Optimal Angiotensin‐Converting Enzyme Inhibitor Dose in Heart Failure?

Thomas

Geltman

2006

Congestive Heart Failure

View full text Add to dashboard Cite

Doses of angiotensin‐converting enzyme (ACE) inhibitors used in the landmark heart failure trials that demonstrated survival benefit are rarely reached in routine practice. The authors review the current literature regarding optimal dosing of ACE inhibitors in heart failure with specific focus on neurohormonal, functional capacity, and clinical outcomes. Neurohormonal studies have shown that lower ACE inhibitor dosing may provide inadequate suppression of the renin‐angiotensin‐aldosterone system. Higher doses of ACE inhibitors have resulted in greater increments in exercise and functional capacity. Clinically, patients on high‐dose ACE inhibitor therapy had significant reductions in all‐cause mortality or hospitalization, cardiovascular hospitalizations, and heart failure‐specific hospitalizations. There is, however, conflicting evidence, and so continued uncertainty exists regarding optimal dosing. Despite underutilization of ACE inhibitors, there is insufficient evidence to support lower doses. Likewise, limited data exist for doses higher than those used in the landmark trials. Clinicians should therefore attempt to reach target doses in heart failure whenever possible.

show abstract

“…The effectiveness of enalapril at different doses (up to 2, 5, 20, and 60 mg) was investigated in two of these studies, and no significant difference was observed (15,16). As for the ATLAS study, low-dose lisinopril (2.5-5 mg) was compared with high-dose lisinopril (32.5-35 mg).…”

Section: Introductionmentioning

confidence: 99%

Renin-angiotensin system blockade in the treatment of heart failure and the role of valsartan in this treatment

Avcı¹,

İkitimur²,

Karadağ³

et al. 2015

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Heart failure which occurs due to various causes including primarily coronary artery diseases and hypertension is a syndrome with complex physiopathology and clinic that can impair patients' quality of life or lead to death. However, it is well known that the activation of renin-angiotensin system (RAS) has an important role in the physiopathology of heart failure with reduced ejection fraction. Therefore, suppression of this system for achieving a gain in the treatment of the disease has been among prominent concerns. In this review, the place of RAS suppressive drugs and valsartan, which is an angiotensin receptor blocker, in heart failure will be examined. (Anadolu Kardiyol Derg 2014; 14(Suppl 2): S1-S8)

show abstract

Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study

Abstract: No significant differences were found in survival and clinical and hemodynamic variables between patients receiving standard and those receiving high doses of enalapril.

Cited by 71 publications

References 30 publications

What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients?

What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients?

What is the Optimal Angiotensin‐Converting Enzyme Inhibitor Dose in Heart Failure?

Renin-angiotensin system blockade in the treatment of heart failure and the role of valsartan in this treatment

Contact Info

Product

Resources

About